Sun Pharma is currently trading at Rs. 1670.00, up by 8.70 points or 0.52% from its previous closing of Rs. 1661.30 on the BSE.

The scrip opened at Rs. 1667.85 and has touched a high and low of Rs. 1677.95 and Rs. 1660.20 respectively. So far 65340 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1960.20 on 30-Sep-2024 and a 52 week low of Rs. 1492.55 on 25-Jun-2024.

Last one week high and low of the scrip stood at Rs. 1686.45 and Rs. 1636.00 respectively. The current market cap of the company is Rs. 400880.89 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.66% and 8.87% respectively.

Sun Pharmaceutical Industries’ partner Philogen S.p.A (Philogen) has voluntarily withdrawn the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy, a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. Philogen’s candidate Nidlegy is partnered with Sun Pharmaceutical Industries for the treatment of Skin Cancers in Europe, New Zealand and Australia.

Philogen's decision to withdraw the Marketing Authorization Application (MAA) was due to the timing of the availability of Chemistry Manufacturing and Controls (CMC) and additional clinical data to better characterize the benefit:risk profile in patients with locally advanced resectable melanoma. Provision of the CMC and clinical data were unlikely to be completed within the current allowed timeframe.

Sun Pharmaceutical Industries (Sun Pharma) is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.